Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study

Orazio Caffo, Ugo De Giorgi, Lucia Fratino, Daniele Alesini, Vittorina Zagonel, Gaetano Facchini, Donatello Gasparro, Cinzia Ortega, Marcello Tucci, Francesco Verderame, Enrico Campadelli, Giovanni Lo Re, Giuseppe Procopio, Roberto Sabbatini, Maddalena Donini, Franco Morelli, Donata Sartori, Paolo Zucali, Francesco Carrozza, Alessandro D'AngeloGiovanni Vicario, Francesco Massari, Daniele Santini, Teodoro Sava, Caterina Messina, Giuseppe Fornarini, Leonardo La Torre, Riccardo Ricotta, Michele Aieta, Claudia Mucciarini, Fable Zustovich, Sveva Macrini, Salvatore Luca Burgio, Sandra Santarossa, Carmine D'Aniello, Umberto Basso, Sara Tarasconi, Enrico Cortesi, Consuelo Buttigliero, Fiorella Ruatta, Antonello Veccia, Vincenza Conteduca, Francesca Maines, Enzo Galligioni

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The availability of new agents (NAs) active in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel treatment (abiraterone acetate, cabazitaxel, and enzalutamide) has led to the possibility of using them sequentially to obtain a cumulative survival benefit. Objective: To provide clinical outcome data relating to a large cohort of mCRPC patients who received a third-line NA after the failure of docetaxel and another NA. Design, setting, and participants: We retrospectively reviewed the clinical records of patients who had received at least two successive NAs after the failure of docetaxel. Outcome measurements and statistical analysis: The independent prognostic value of a series of pretreatment covariates on the primary outcome measure of overall survival was assessed using Cox regression analysis. Results and limitations: Weassessed260patientswhoreceivedonethird-lineNAbetween January 2012 and December 2013, including 38 who received a further NA as fourth-line therapy. The median progression-free and overall survival from the start of third-line therapy was, respectively, 4 mo and 11 mo, with no significant differences between the NAs. Performance status, and haemoglobin and alkaline phosphatase levels were the only independent prognostic factors. The limitations of the study are mainly due its retrospective nature and the small number of patients treatedwith some of the sequences. Conclusions: We were unable to demonstrate a difference in the clinical outcomes of third-line NAs regardless of previous NA therapy. Patient summary: It is debated which sequence of treatments to adopt after docetaxel. Our data do not support the superiority of any of the three new agents in third-line treatment, regardless of the previously administered new agent.

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalEuropean Urology
Volume68
Issue number1
DOIs
Publication statusPublished - 2015

Keywords

  • Abiraterone acetate
  • Cabazitaxel
  • Cancer
  • Castration-resistant prostate
  • Enzalutamide
  • Fourth line
  • Prognostic factors
  • Third line

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study'. Together they form a unique fingerprint.

Cite this